Overview

Effect of Roflumilast at Acute Exacerbations of Chronic Obstructive Pulmonary Disease

Status:
Terminated
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to investigate if roflumilast can reduce the neutrophilic inflammation at acute exacerbations of Chronic Obstructive Pulmonary Disease (COPD). In addition, the potential benefit of roflumilast on severity and recovery periods of acute COPD exacerbations will be assessed using patient diaries and questionnaires.
Phase:
Phase 2
Details
Lead Sponsor:
AstraZeneca
Takeda